Back to Search
Start Over
High hopes for RANKL: will the mouse model live up to its promise?
- Source :
- Breast Cancer Research : BCR, Breast cancer research : BCR
- Publisher :
- BioMed Central
-
Abstract
- The steroid hormones, estrogens and progesterone are key drivers of postnatal breast development and are linked to breast carcinogenesis. Experiments in the mouse mammary gland have revealed that they rely on paracrine factors to relegate their signal locally and to amplify it. In particular, RANKL is a key mediator of progesterone action. Systemic inhibition of RANKL blocked proliferation in the mammary epithelium with potential clinical implications: a RANKL-inhibiting antibody, Denosumab (Amgen), has been approved by the US Food and Drug Administration for osteoporosis treatment. Two publications now provide evidence that progestin-driven mouse mammary tumorigenesis can be blocked by ablating RANK signaling. Can the osteoporosis drug help breast cancer patients? The burning question now is whether the role of this pathway is conserved in the human breast and whether RANKL signaling has a role in the pathogenesis of one or more subtypes of breast cancer.
- Subjects :
- 03 medical and health sciences
Paracrine signalling
0302 clinical medicine
Breast cancer
Mediator
Viewpoint
Surgical oncology
Morphogenesis
Animals
Humans
Medicine
Breast-Cancer
030304 developmental biology
0303 health sciences
Breast development
biology
business.industry
RANK Ligand
Mammary Neoplasms, Experimental
medicine.disease
3. Good health
Cell Transformation, Neoplastic
Denosumab
RANKL
030220 oncology & carcinogenesis
Immunology
Cancer research
biology.protein
Female
Progestins
business
Hormone
medicine.drug
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Breast Cancer Research : BCR, Breast cancer research : BCR
- Accession number :
- edsair.doi.dedup.....d358e360e5bc1f07ef72075c3ffd3bdc